Información*
| Nombre | VICTOR MANUEL OYERVIDES JUAREZ |
|---|---|
| Área | MEDICINA Y CIENCIAS DE LA SALUD |
| Campo | ESPECIALIDAD MÉDICA |
| Disciplina | ONCOLOGÍA |
| Especialidad | ONCOLOGIA |
| CVU | 552939 |
| Institución | |
|---|---|
| Dependencia | FACULTAD DE MEDICINA |
| Entidad | NUEVO LEON |
| Nivel | 1 |
| Vigencia | Inicio: 01/01/2024 |
| Fin: 31/12/2028 |
* Información del primer trimestre de 2026.
Fuente: SECIHTI.
Publicaciones ORCID
- 2022
- A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. Lung cancer (Amsterdam, Netherlands)
- Applicability of a web app for breast cancer risk calculation and personalized recommendations for screening in Mexico. Journal of Clinical Oncology
- Applicability of a web app for lung cancer risk calculation and personalized recommendations for screening in Mexico. Journal of Clinical Oncology
- 2021
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine
- 2020
- Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab Current Problems in Cancer: Case Reports
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial Annals of Oncology
- Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma. Journal of investigational allergology & clinical immunology
- Access to molecular testing and targeted molecular therapy among Mexican patients with lung adenocarcinoma. Journal of Clinical Oncology